1. Cholesterol biosynthesis regulation and protein changes in rat liver following treatment with fluvastatin
- Author
-
Angel M. Aponte, Ricardo Esquer-Blasco, Anthony J. Makusky, Christine L. Gatlin, Sandra Steiner, Michael D Seonarain, John Lennon, N. Leigh Anderson, and Andrew M. McGrath
- Subjects
Male ,7-Dehydrocholesterol reductase ,medicine.medical_specialty ,Indoles ,Statin ,Proteome ,medicine.drug_class ,Reductase ,Biology ,Toxicology ,Fatty Acids, Monounsaturated ,chemistry.chemical_compound ,Internal medicine ,medicine ,Animals ,Fluvastatin ,chemistry.chemical_classification ,Cholesterol ,Proteins ,General Medicine ,Lipid Metabolism ,Hydroxymethylglutaryl-CoA reductase ,Rats, Inbred F344 ,Rats ,Endocrinology ,Enzyme ,Liver ,chemistry ,HMG-CoA reductase ,biology.protein ,Carbohydrate Metabolism ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,medicine.drug - Abstract
The enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase is a key regulator in cholesterol biosynthesis and HMG CoA reductase inhibitors (statins) have become a widely prescribed family of lipid lowering agents. Cholesterol synthesis occurs predominantly in liver which is the target organ of statins. We studied the effects of fluvastatin (Lescol®), a member of the statin family, on hepatic protein regulation. Male F344 rats treated with 0.8 mg/kg per day fluvastatin or 24 mg/kg per day fluvastatin for 7 days showed treatment-related changes in 58 liver proteins (P
- Published
- 2001
- Full Text
- View/download PDF